DelveInsight Business Research LLP
Albany, NY -- (SBWIRE) -- 12/13/2019 -- Alpha-1 Anti-Trypsin Deficiency Market Insights, Epidemiology and Market Forecast-2028
(Albany, US) DelveInsight launched a new report on Alpha-1 Anti-Trypsin Deficiency Market Insights, Epidemiology and Market Forecast-2028
Some of the key facts of the report
1. Approximately 15 per cent of adults with Alpha-1 Anti-trypsin Deficiency develop liver
damage (cirrhosis) due to the formation of scar tissue in the liver.
2. Women and men are affected in equal numbers.
Key benefits of the report
1. Alpha-1 Anti-Trypsin Deficiency market report covers a descriptive overview and comprehensive insight of the Alpha-1 Anti-Trypsin Deficiency epidemiology and Alpha-1 Anti-Trypsin Deficiency market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alpha-1 Anti-Trypsin Deficiency market report provides insights on the current and emerging therapies.
3. Alpha-1 Anti-Trypsin Deficiency market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alpha-1 Anti-Trypsin Deficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alpha-1 Anti-Trypsin Deficiency market.
Request for sample pages
The main goal to manage alpha1 anti-trypsin deficiency is to prevent or slow the progression of lung disease. Most patients are identified after they develop lung disease, and the goals of treating alpha1-antitrypsin deficiency emphysema are likely to those for treating all forms of emphysema.
Emphysema treatments are associated with Alpha 1 Anti-Trypsin Deficiency that include standard medications used in managing patients with emphysema of all causes (such as inhaled bronchodilators, inhaled steroids, anticholinergics, oxygen therapy, and the administration of antibiotics or phosphodiesterase five inhibitors for the frequent respiratory infections) as well as (in specific subgroups) specific Alpha 1 Anti-Trypsin Deficiency treatment which is known as augmentation therapy. Exercise programs (pulmonary rehabilitation) and good nutrition may help increase the overall quality of daily living.
There are several Alpha1 Anti-Trypsin deficiency treatments that can be effective in. However, they have many limitations. No specific therapy is available for liver disease associated with the disease. Currently, management is directed at controlling symptoms. So, there is a high urgent need for novel therapies that can treat the liver disease associated with Alpha1 Anti -Trypsin deficiency and can overcome the limitations of existing therapies.
The launch of the emerging therapies is expected to significantly impact Alpha1 Anti -Trypsin deficiency treatment scenario in the upcoming years:-
2. Inhaled AAT
And many others
The key players in Alpha1 Anti -Trypsin deficiency market are:
1. Mereo BioPharma
And many others
Table of contents
1. Report Introduction
2. Alpha-1 Anti-trypsin Deficiency Market Overview at a Glance
3. Alpha-1 Anti-trypsin Deficiency Disease Background and Overview
4. Alpha-1 Anti-trypsin Deficiency Epidemiology and Patient Population
5. Alpha-1 Anti-trypsin Deficienc Country- Wise Epidemiology
5.1. United States
5.2.5. United Kingdom
6. Alpha-1 Anti-trypsin Deficiency Treatment and Medical Practices
7. Alpha-1 Anti-trypsin Deficiency Marketed Drugs
7.1. Prolastin: Talecris Biotherapeutics
7.2. Aralast: Baxter International
8. Alpha-1 Anti-trypsin Deficiency Emerging Therapies
8.1. Key Cross Competition
8.2. MPH-966: Mereo BioPharma
8.3. Inhaled AAT: Kamada
9. Alpha-1 Anti-trypsin Deficiency Market Size
9.1. Key Findings
9.2. Total 7MM Alpha-1 Anti-trypsin Deficiency Market analysis
10. 7MM Alpha-1 Anti-trypsin Deficiency Country-Wise Market Analysis
10.1. United States
10.4. United Kingdom
11. Market Drivers
12. Market Barriers
14. Report Methodology
15. DelveInsight Capabilities
17. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.